Semaglutide and liraglutide are glucagon-like peptide-1 receptor agonists (GLP-1 RAs), increasingly used in adolescents with severe obesity, while phentermine/topiramate extended release (ER) and orlistat represent older oral options. This evidence concerns the gene GLP1R and obesity disorder.